Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 175

Similar articles for PubMed (Select 12650799)

1.

Health-state utilities and quality of life in hepatitis C patients.

Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, Krahn M.

Am J Gastroenterol. 2003 Mar;98(3):630-8.

PMID:
12650799
2.

Does cirrhosis affect quality of life in hepatitis C virus-infected patients?

Hsu PC, Krajden M, Yoshida EM, Anderson FH, Tomlinson GA, Krahn MD.

Liver Int. 2009 Mar;29(3):449-58. doi: 10.1111/j.1478-3231.2008.01865.x.

PMID:
19267865
3.

Estimation of utilities for chronic hepatitis C from SF-36 scores.

Thein HH, Krahn M, Kaldor JM, Dore GJ.

Am J Gastroenterol. 2005 Mar;100(3):643-51.

PMID:
15743364
4.

Health-state utilities in liver disease: a systematic review.

McLernon DJ, Dillon J, Donnan PT.

Med Decis Making. 2008 Jul-Aug;28(4):582-92. doi: 10.1177/0272989X08315240. Epub 2008 Apr 18. Review.

PMID:
18424560
5.

Health values of patients with chronic hepatitis C infection.

Sherman KE, Sherman SN, Chenier T, Tsevat J.

Arch Intern Med. 2004 Nov 22;164(21):2377-82.

PMID:
15557419
6.

The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons.

Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH.

Value Health. 2008 May-Jun;11(3):527-38. doi: 10.1111/j.1524-4733.2007.00297.x. Epub 2007 Dec 17.

PMID:
18179664
7.

The cost-effectiveness of testing for hepatitis C in former injecting drug users.

Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K.

Health Technol Assess. 2006 Sep;10(32):iii-iv, ix-xii, 1-93.

8.

Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index.

Dan AA, Kallman JB, Srivastava R, Younoszai Z, Kim A, Younossi ZM.

Liver Transpl. 2008 Mar;14(3):321-6. doi: 10.1002/lt.21376.

9.

Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C.

John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, Yoshida EM, Anderson FH, Krahn MD.

Am J Gastroenterol. 2009 Oct;104(10):2439-48. doi: 10.1038/ajg.2009.346. Epub 2009 Jun 30.

PMID:
19568230
10.

Patient and community preferences for outcomes in prostate cancer: implications for clinical policy.

Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, Trachtenberg J, Naglie G.

Med Care. 2003 Jan;41(1):153-64.

PMID:
12544552
11.

Assessment of utilities and health-related quality of life in patients with chronic liver disease.

Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G.

Am J Gastroenterol. 2001 Feb;96(2):579-83.

PMID:
11232711
12.

Patient utilities in fibromyalgia and the association with other outcome measures.

Bakker C, Rutten M, van Santen-Hoeufft M, Bolwijn P, van Doorslaer E, Bennett K, van der Linden S.

J Rheumatol. 1995 Aug;22(8):1536-43.

PMID:
7473480
13.

Health state utilities and quality of life in patients with hepatitis B.

Woo G, Tomlinson G, Yim C, Lilly L, Therapondos G, Wong DK, Ungar WJ, Einarson TR, Sherman M, Heathcote JE, Krahn M.

Can J Gastroenterol. 2012 Jul;26(7):445-51.

14.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

15.

Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema.

Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M.

Br J Dermatol. 1999 Dec;141(6):1067-75.

PMID:
10606854
16.

A comparison of preference assessment instruments used in a clinical trial: responses to the visual analog scale from the EuroQol EQ-5D and the Health Utilities Index.

Glick HA, Polsky D, Willke RJ, Schulman KA.

Med Decis Making. 1999 Jul-Sep;19(3):265-75. Erratum in: Med Decis Making 1999 Oct-Dec;19(4):511.

PMID:
10424833
17.

Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J.

Pharmacoeconomics. 2004;22(4):257-65.

PMID:
14974875
18.

Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.

Hornberger J, Torriani FJ, Dieterich DT, Bräu N, Sulkowski MS, Torres MR, Green J, Patel K.

J Clin Virol. 2006 Aug;36(4):283-91. Epub 2006 Jun 9.

PMID:
16765638
19.

Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure.

Havranek EP, McGovern KM, Weinberger J, Brocato A, Lowes BD, Abraham WT.

J Card Fail. 1999 Jun;5(2):85-91.

PMID:
10404347
20.

A comparison of the EuroQol-5D and the Health Utilities Index mark 3 in patients with rheumatic disease.

Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH, Vasoo S, Li SC, Thumboo J.

J Rheumatol. 2003 Oct;30(10):2268-74.

PMID:
14528528
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk